Evidence map›Paper›PMID 31360234›Full record

ReviewEuropean cardiology2019

Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases.

Kana Shimizu, Masafumi Funamoto, Yoichi Sunagawa, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto

Open access · goldAbstract readReview
In one paragraph

Review in European cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 91 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Effectiveness of Novel Drug Delivery System using Curcumin in Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. The Effects of Curcumin on Inflammasome: Latest Update.Molecules (Basel, Switzerland) · 2023
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kana ShimizuDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Masafumi FunamotoDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Yoichi SunagawaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Satoshi ShimizuDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Yasufumi KatanasakaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Yusuke MiyazakiDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Hiromichi WadaClinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto, Japan.
Koji HasegawaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Tatsuya MorimotoDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka, Japan.
Kyoto Medical Center · JPUniversity of Shizuoka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation plays a significant role in lifestyle-related diseases, such as cardiovascular diseases and obesity/impaired glucose tolerance. Curcumin is a natural extract that possesses numerous physiological properties, as indicated by its anti-inflammatory action. The mechanisms underlying these effects include the inhibition of nuclear factor-kappaB and Toll-like receptor 4-dependent signalling pathways and the activation of a peroxisome proliferator-activated receptor-gamma pathway. However, the bioavailability of curcumin is very low in humans. To resolve this issue, several drug delivery systems have been developed and a number of clinical trials have reported beneficial effects of curcumin in the management of inflammation-related diseases. It is expected that evidence regarding the clinical application of curcumin in lifestyle-related diseases associated with chronic inflammation will accumulate over time.

Indexed as

cardiovascular risk factorcurcuminInflammationlifestyle-related diseasesnatural product

Identifiers

PMID31360234
PMCPMC6659038
OpenAlexW2956607058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.